EDO-S101, HDACi Fusion, Clinical Trials, T-Cell Lymphoma

Study of EDO-S101, A First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies

Active, not recruiting new patients.

This study evaluates the efficacy, safety and pharmacokinetics of EDO-S101 in patients with relapsed/refractory hematologic malignancies. All patients will receive EDO-S101.

Study Type:  Interventional

Study Design:  

Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Official Title:  A Phase 1 Study to Investigate the Safety, Pharmacokinetic Profiles and the Efficacy of EDO-S101, a First-in-Class Alkylating Histone Deacetylase Inhibition (HDACi) Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies


Hematological Malignancies
Multiple Myeloma
Hodgkin's Lymphoma
Peripheral T-cell Lymphoma
Non-Hodgkin's Lymphoma

Intervention:  Drug: EDO-S101

Phase:  Phase 1

External Link:  https://clinicaltrials.gov/ct2/show/study/NCT02576496